Angiogenesis inhibitors have shown clinical benefits in patients with advanced cancer, but further therapeutic improvement is needed. We have previously shown that the zinc finger protein 36, C3H type-like 1 (ZFP36L1) enhances vascular endothelial growth factor (VEGF) mRNA decay through its interaction with AU-rich elements within VEGF 3 0 -untranslated region. In this study, we evaluated the possibility to develop an antiangiogenic and antitumoral strategy using the mRNA-destabilizing activity of ZFP36L1. We engineered a cell-penetrating ZFP36L1, by fusing it to the protein transduction domains (PTDs) TAT derived from HIV, or the polyarginine peptides R7 or R9. PTD-ZFP36L1 fusion proteins were expressed in bacterial cells and affinity-purified to homogeneity. TAT-, R7-and R9-ZFP36L1 were efficiently internalized into living cells and decreased both endogenous VEGF mRNA half-life and VEGF protein levels in vitro. Importantly, a single injection of R9-TIS11b fusion protein into a high-VEGF expressing tissue in vivo (in this study, the mouse adrenal gland) markedly decreased VEGF expression. We further evaluated the effect of R9-ZFP36L1 on tumor growth using Lewis Lung Carcinoma (LL/2) cells implanted subcutaneously into nude mice. Intratumoral injection of R9-ZFP36L1 significantly reduced tumor growth and markedly decreased the expression of multiple angiogenic and inflammatory cytokines, including VEGF, acidic fibroblast growth factor, tumor necrosis factor a, interleukin (IL)-1a and IL-6, with a concomitant obliteration of tumor vascularization. These findings indicate that R9-ZFP36L1 fusion protein may represent a novel antiangiogenic and antitumoral agent, and supports the emerging idea that modulation of mRNA stability represents a promising therapeutic approach to treat cancer.
Introduction
Increased vascular endothelial growth factor (VEGF) expression is associated with many angiogenesis dependent pathologies, such as cancer (Ferrara, 2004) and ocular diseases (Gariano et al., 2006) . Therefore, intensive efforts have been undertaken over the past decade to develop therapeutic strategies in order to inhibit the pathological angiogenesis via neutralization of VEGF or its receptors by antibodies, or blocking VEGF receptor activation and signaling with tyrosine kinase inhibitors (Ellis and Hicklin, 2008) . There has been success in combining antiangiogenic agents with conventional chemotherapy, such as the successful use of the monoclonal anti-VEGF antibody bevacizumab (Avastin, Genentech/Roche Laboratories, San Francisco, CA, USA) with various chemotherapies for metastatic colorectal, renal, non-small-cell lung and metastatic breast cancer (Ellis and Hicklin, 2008) . However, despite the initial enthusiasm predicting the absence of resistance to these antiangiogenic treatments, such resistance appeared to occur on time (Bergers and Hanahan, 2008) . There is therefore a real need for a variety of antiangiogenic drugs that will target the angiogenic process through distinct mechanisms.
VEGF expression is regulated by transcriptional and post-transcriptional mechanisms. At the post-transcriptional level, VEGF mRNA stability is tightly controlled (Levy, 1998; Ciais et al., 2004; Onesto et al., 2004; Cherradi et al., 2006) . VEGF mRNA stability is regulated by the binding of stabilizing and destabilizing proteins to AU-rich elements (AREs) located in the 3 0 -untranslated region (3 0 -UTR) of VEGF mRNA. We have previously characterized ZFP36L1 as a VEGF mRNA-destabilizing protein (Ciais et al., 2004) . ZFP36L1 is a member of the tristetraprolin (TTP) family of CCCH tandem zinc-finger proteins, consisting of three members, which are expressed in all mammals (TTP also named TIS11 or ZFP36, ZFP36L1 also named TIS11b or BRF1 and ZFP36L2 also named TIS11d or BRF2) and a fourth member only present in rodents (ZFP36L3). All four proteins bind and destabilize ARE-containing mRNAs in vitro (Baou et al., 2009 ). However, gene knockout studies have provided evidence for their unique role in vivo (Carballo et al., 1998; Stumpo et al., 2004 Stumpo et al., , 2009 ). ZFP36L1 knockout mice are embryonic lethal because of abnormal placentation and major vascular defects. Both TTP and ZFP36L1 enhance the decay of their targets by association with the mRNA decay machinery (Lykke-Andersen and Wagner, 2005) .
Protein transduction domains (PTDs) have emerged as novel tools for delivering biologically active macromolecules into cells (Schwarze et al., 1999) . The HIV-1 transactivator TAT is capable of crossing the plasma membrane and thereby mediating the intracellular delivery of heterologous proteins (Chauhan et al., 2007) . Most of the recent studies indicate that PTDs use various forms of endocytosis (Richard et al., 2003; Snyder and Dowdy, 2004; Asoh and Ohta, 2008) . They have been used to deliver a variety of cargos including proteins, peptides and nucleic acids in vitro, and to successfully treat several preclinical models of human diseases such as cancer and cerebral ischemia (Lindsay, 2002; Snyder and Dowdy, 2004; Asoh and Ohta, 2008) . The homopolymers of arginine have been shown to transduce various cell types with higher efficiencies than the 11 amino-acids of TAT (Wender et al., 2000; Futaki et al., 2001; Ho et al., 2001) .
In this study, we hypothesized that fusion of ZFP36L1 to a PTD would allow delivery of ZFP36L1 into cells and target not only VEGF but also a number of inflammatory cytokines and products of stressresponse genes whose mRNA 3 0 -UTRs possess AREs. We confirmed this hypothesis by demonstrating that cell-penetrating R9-ZFP36L1 markedly reduces the physiological expression of VEGF in vivo and leads to a significant inhibition of tumor growth and vascularization with a concomitant downregulation of VEGF and several proangiogenic inflammatory cytokines. After proper vectorization, ZFP36L1 might thus represent a promising second generation antiangiogenic and antitumorigenic agent.
Results
Overexpressed PTD-ZFP36L1 fusion proteins decrease reporter gene activity through VEGF 3 0 -UTR A previous study using transfection of a ZFP36L1 expression vector and a reporter gene construct comprising the firefly luciferase cDNA, cloned upstream of VEGF mRNA 3 0 -UTR (Luc-3 0 -UTR), allowed us to demonstrate that VEGF mRNA 3 0 -UTR mediates a ZFP36L1-induced decrease in reporter gene activity, which was because of a decrease in luciferase transcript stability (Ciais et al., 2004) . In order to check that the fusion of TAT, R7 or R9 to ZFP36L1 does not alter ZFP36L1 function, we first analyzed the effect of each fusion protein on luciferase activity of Luc-3 0 -UTR construct. COS7 cells were transfected with increasing doses of expression vectors encoding ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 (Figure 1a) , and a fixed concentration of Luc-3 0 -UTR (500 ng). The expression level of each construct was assessed in COS7 cell lysates by western blot (Figure 1b) . Luciferase activity was markedly decreased by ZFP36L1 and PTD-ZFP36L1 in a dose-dependent manner (Figure 1c ). The effect of ZFP36L1 was not statistically different from Western blot analysis of the expression levels of ZFP36L1 and PTD-ZFP36L1 constructs in COS7 cells showing that ZFP36L1, and the fusion proteins TAT-, R7-and R9-ZFP36L1 are equally expressed at each dose of the transfected plasmid. Control cells refer to transfection with pTarget empty vector. The apparent molecular weight of ZFP36L1 and PTD-ZFP36L1 proteins (TAT-, R7-and R9-ZFP36L1) were 48 and 51 kDa, respectively. (c) Dose-dependence of the inhibitory effect of ZFP36L1 and PTD-ZFP36L1 on VEGF mRNA 3 0 -UTR-mediated luciferase activity. COS7 cells were transfected with various amounts of ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 pTarget plasmids in the presence of 500 ng of pLuc-3 0 -UTR (Firefly luciferase) and 25 ng of pRL-TK (Renilla luciferase) plasmids for 24 h as described in Supplementary Materials and Methods. The pLuc-3 0 -UTR construct contains the full-length 3 0 -UTR of rat VEGF mRNA (2201 bp) (Ciais et al., 2004) . Firefly luciferase and Renilla luciferase activities were measured as stated in Supplementary Materials and Methods. Results are expressed as relative light units of firefly luciferase activity over relative light units of Renilla luciferase activity to compensate for variations in transfection efficiency and are represented as a percentage of luciferase activity in control cells transfected with empty vector. With 25 ng of ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 transfected plasmids, luciferase activity was 33.6 ± 6.5 (ZFP36L1), 43.5 ± 9.7 (TAT-ZFP36L1), 42.2 ± 9 (R7-ZFP36L1) and 46.5 ± 5.6% (R9-ZFP36L1) of controls (Po0.001, n ¼ 3). Transfections were performed in triplicate and values are means ± s.e.m. from four independent experiments. Each value was compared to its respective control using ANOVA with Dunnett's post-test. **, ***, significantly different from control with Po0.01 and Po0.001, respectively.
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PTD-ZFP36L1 fusion proteins enhance endogenous VEGF mRNA decay and impair VEGF protein production In order to investigate the effect of ZFP36L1 and PTD-ZFP36L1 proteins on endogenous VEGF mRNA stability, COS7 cells were transfected either with ZFP36L1, TAT-ZFP36L1 and R7-ZFP36L1, or with R9-ZFP36L1 expression vectors then used in 5,6-dichloro-1-b-d-ribofuranosylbenzimidazole (DRB) time course experiments. Overexpression of ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 and R9-ZFP36L1 triggered rapid VEGF mRNA decay in COS7 cells with a halflife of 62 ± 4, 56 ± 3, 65 ± 6 and 71 ± 5 min, respectively, as compared with 101±10 min for control cells transfected with an empty plasmid ( Figures 2a and b , left panel). ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 and R9-ZFP36L1 decreased the steady state level of VEGF mRNA to 61 ± 10, 62 ± 9, 43 ± 6 and 52 ± 5% of control, respectively ( Figure 2b , right panel). ELISA analysis of culture medium from COS7 cells revealed that ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 and R9-ZFP36L1 reduced the VEGF secretion down to 47.9 ± 1.9, 46.6 ± 8.4, 54.4 ± 7.6 and 48.5 ± 4.2% of control, respectively ( Figure 2c ). These data indicated that ZFP36L1-and PTD-ZFP36L1-induced decreases in VEGF mRNA stability are accompanied by a decrease in VEGF protein production. This prompted us to produce and purify recombinant fusion proteins.
ZFP36L1 and PTD-ZFP36L1 protein production and purification We constructed negative control ZFP36L1 without PTD and PTD-ZFP36L1 bacterial expression vectors. Expression and purification of the recombinant proteins are described in details in Supplementary Materials and Methods. The major problems encountered during our initial production and purification procedures were the accumulation of PTD-ZFP36L1 proteins into inclusion bodies, as well as their precipitation, thus confirming the difficulty of expressing and purifying TTP family members from various expression systems (Cao, 2004; Cao et al., 2008; Cao and Lin, 2009 ). However, we succeeded in increasing the solubility of PTD-ZFP36L1 fusion proteins by lowering the expression temperature and optimizing the isopropyl b-D-1-thiogalactopyranoside treatment. In addition, an increased stability was observed in the presence of zinc chloride (100 mM). Figure 3A illustrates the different steps of TAT-ZFP36L1 purification on a Flag-affinity chromatography column. Purification of ZFP36L1, R7-and R9-ZFP36L1 was achieved using the same procedure. SDS-PAGE analysis of the eluates identified homogeneous preparations for ZFP36L1 and PTD-ZFP36L1 proteins with expected molecular weights of 38 and 42 kDa, respectively ( Figure 3B ). It is worth mentioning that overexpression of ZFP36L1 in bacteria yields a 38 kDa protein (in agreement with the molecular weight deduced from the amino-acid sequence), whereas overexpression in mammalian cells yields a 48 kDa protein (Figure 1b) , indicating post-translational modifications of ZFP36L1 in mammals.
PTD-ZFP36L1 fusion proteins are efficiently delivered into live cells Internalization of purified ZFP36L1 (negative control) and PTD-ZFP36L1 proteins was examined in live cells. COS7 cells were incubated with 100 nM of Alexa Fluor 488 dye-labeled ZFP36L1 or PTD-ZFP36L1 for 2 h. Fluorescence microscopy analysis showed that very little staining was detected in COS7 cells incubated with Alexa-labeled ZFP36L1 (Figure 4a ). In contrast, we observed a significant uptake of Alexa-labeled R9-ZFP36L1 (green fluorescent signal), which indicates that R9 was efficient in delivering ZFP36L1 to cell cytoplasm ( Figure 4a ). In addition, evidence for successful PTD-ZFP36L1 intracellular delivery was provided by confocal scanning microscopy ( Figure 4b ). Internalized TAT-ZFP36L1 and R9-ZFP36L1 were distributed throughout the cytoplasm with a punctuate appearance, indicative of localization in transport vesicles like endosomes. Deconvolution of the confocal microscopy images along the z axis confirmed that R9-ZFP36L1 was indeed internalized in the COS7 cell cytoplasm ( Figure 4c ).
PTD-ZFP36L1 fusion proteins inhibit VEGF mRNA and protein expression in live cells
We next evaluated the effect of TAT-, R7-or R9-ZFP36L1 purified proteins on endogenous VEGF mRNA levels. COS7 cells were incubated with 100 nM of protein for 24 h and VEGF mRNA was analyzed by northern blot (Figure 5a ). Internalization of TAT-, R7-and R9-ZFP36L1 in two independent experiments reduced VEGF mRNA steady state levels to 63.3 ± 10.1, 44.4 ± 5.3 and 49.8 ± 3.1% of control level (vehicle), respectively ( Figure 5b ). ZFP36L1, which has no cellpenetrating ability, displayed only a discrete effect on the basal expression of VEGF mRNA (80.4 ± 9.6% of control level). We further investigated whether the PTD-ZFP36L1-induced decreases in VEGF mRNA was accompanied by decreases in VEGF protein production. As shown in Figure 5c , VEGF amounts in the culture medium from R7-ZFP36L1-and R9-ZFP36L1-transduced COS7 cells were significantly decreased to 64.4 ± 10.8 and 63.03 ± 14.1% of control cells (n ¼ 3, Po0.05). No significant effect of TAT-ZFP36L1 on VEGF secretion was observed. This latter result is in contrast to the one obtained in transfection experiments, which showed a marked inhibition of VEGF secretion in TAT-ZFP36L1 transfected cells ( Figure 1c ). The above results led us to choose R9-ZFP36L1 fusion protein to examine the effect of ZFP36L1 transduction on VEGF expression in vivo. 6 cells/well) with 5 ng of either pTarget empty plasmid (control cells) or ZFP36L1 or PTD-ZFP36L1 plasmids. At 48 h after transfection, the transcription inhibitor 5,6-dichloro-1-b-d-ribofuranosylbenzimidazole (10 mg/ml) was added and total RNA was extracted at the time points indicated and analyzed by northern blot. The membrane was hybridized to a radiolabeled VEGF 3 0 -UTR probe and rehybridized to 18S RNA probe for loading control. Membranes were exposed either overnight or for 6 h for VEGF mRNA or 18S RNA detection, respectively. The two arrows indicate the two major species of VEGF mRNA detected in COS7 cells. Shown is a representative northern blot of three independent experiments. (b) Left panel: measurement of VEGF mRNA half-life in COS7 cells transfected as described in (a). VEGF mRNA values were normalized to 18S RNA values and plotted as a percentage of the initial value against time. The data shown represent the mean ± s.e.m. of three independent experiments. Each value was compared with its respective control (pTarget empty plasmid) using ANOVA with Dunnett's post-test. For t ¼ 30 min, ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 and R9-ZFP36L1 were not significantly different from control. For t ¼ 60 min, ZFP36L1 and TAT-ZFP36L1 were significantly different from control with Po0.01, and R7-ZFP36L1 and R9-ZFP36L1 were significantly different from control with Po0.05. For t ¼ 120 and 180 min, ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 and R9-ZFP36L1 were significantly different from control with Po0.01). Right panel: Quantification of VEGF mRNA steady state levels at time 0 before addition of 5,6-dichloro-1-b-d-ribofuranosylbenzimidazole. Each point represents the mean± s.e.m. of three independent experiments performed in triplicate (*, **, significantly different from control with Po0.05 and Po0.01, respectively). (c) Dose-dependence of the inhibitory effect of ZFP36L1 and PTD-ZFP36L1 on VEGF protein levels in COS7 cells transfected with increasing amounts of ZFP36L1 and PTD-ZFP36L1. At 24 h after transfection, VEGF protein was measured in the culture medium by ELISA. VEGF protein values were normalized to total protein values and represented as a percentage of VEGF protein level in control cells. Each point is the mean ± s.d. of triplicate samples from an experiment representative of three similar experiments.
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Injection of R9-ZFP36L1 into adrenocortical tissue induces a marked reduction in VEGF protein expression The adrenal cortex is a steroid hormone-producing tissue and one of the most highly vascularized tissues in the organism. To evaluate the bioactivity of R9-ZFP36L1 on VEGF expression in vivo, the fusion proteins were injected in the adrenal glands of severe combined immunodeficiency mice. Immunohistochemical analysis of VEGF revealed a strong and uniform staining in the adrenal cortex of control mice ( Figure 6a , M1 and M2 mice). At 24 h after R9-ZFP36L1 injection, a marked decrease in VEGF staining was observed throughout the entire zona fasciculata-reticularis of the adrenal cortex ( Figure 6a , M3 and M4 mice). Some VEGF immunoreactivity was still detected in the zona glomerulosa, the outer part of the adrenal cortex. While the capillaries in the zona fasciculata-reticularis paralleled the columns of steroidogenic cells in control animals, the vascular network in R9-ZFP36L1-treated animals appeared discontinuous. These histological modifications were reminiscent of those obtained during dexamethasone-induced adrenal cortex regression, a condition when VEGF protein levels are also dramatically reduced (Thomas et al., 2004) . In order to check whether R9-ZFP36L1-mediated decrease in VEGF protein expression in the adrenal cortex was correlated with VEGF mRNA levels, the expression of the different VEGF mRNA isoforms was analyzed by RT-PCR (Figure 6b ). R9-ZFP36L1 injection downregulates the levels of all VEGF mRNA isoforms detected in mouse adrenal cortex, within 24 h. This effect was even more pronounced at 48 h after injection.
Intratumoral injection of R9-ZFP36L1 inhibits LL/2 tumor growth
We next evaluated the effect of R9-ZFP36L1 on the growth of luciferase-expressing Lewis Lung Carcinoma (LL/2) cells' allografts in mice. As the engineered ZFP36L1 was of human origin, these experiments were conducted in nude mice (nu/nu). Tumors were allowed to develop subcutaneously (up to a size of 100 mm 3 ), after which R9-ZFP36L1 (40 ng) or vehicle was injected into the tumors every other day. As shown in Figure 7a , at day 20 post-implantation, R9-ZFP36L1 significantly inhibited LL2 tumor growth by 42% as measured by caliper (mean 1104±116 mm 3 for controls, versus 634 ± 62 mm 3 for R9-ZFP36L1-treated group; n ¼ 5 for each group, Po0.001). Injection of non-penetrating ZFP36L1 (negative control) had no effect on tumor growth (Supplementary Figure 1) . The inhibitory effect R9-ZFP36L1 was confirmed and even more pronounced by measuring luciferase activity of live cells at day 20 using bioluminescence imaging (Figure 7b ). R9-ZFP36L1 induced a 52% reduction in luciferase activity in R9-ZFP36L1-treated tumors (mean activity 
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R9-ZFP36L1 represses multiple tumor angiogenic factors S Planel et al 3.43 Â 10 8 ±7.9 Â 10 7 photons/s for controls versus 1.66 Â 10 8 ± 8 Â 10 7 photons/s for R9-ZFP36L1-treated tumors, n ¼ 4, Po0.05). Differences in luciferase activity correlated with tumor weights (Figure 7c , mean weight 1116 ± 109 mg for controls versus 628 ± 32 mg for R9-ZFP36L1-treated tumors, n ¼ 5, Po0.01). Moreover, R9-ZFP36L1-treated tumors looked much paler than the reddish control ones.
R9-ZFP36L1-induced tumor growth inhibition is associated with reduced microvessel density and decreased VEGF expression To determine whether R9-ZFP36L1 had an effect on LL/2 tumor vasculature, immunohistochemical analysis was performed on resected control and treated tumors ( Figure 8A ). New blood vessel formation was dramatically reduced in R9-ZFP36L1-treated tumors (c and d) as compared with controls (a and b). In addition, vascularization in R9-ZFP36L1-treated tumors was often limited to the periphery of the tumor mass (c). Vessels in control tumors displayed an important variability in diameter compared with the narrow vessels observed in R9-ZFP36L1-treated tumors (b and d). Quantitation of microvessel density in tumor sections revealed that R9-ZFP36L1 decreased microvessel density by 76% ( Figure 8B , mean 91±4.2/200 Â field for control versus 22 ± 1.34/200 Â field for R9-ZFP36L1-treated tumors, n ¼ 3, Po0.0001). As VEGF is a potent inducer of microvessel growth in tumors, we also determined the effect of R9-ZFP36L1 on VEGF expression ( Figure 8C ). VEGF protein levels (brown staining) were significantly decreased in R9-ZFP36L1 treated tumors (g and h) as compared with controls (e and f).
R9-ZFP36L1 targets multiple angiogenic and inflammatory cytokines As ZFP36L1 could target not only VEGF but also a number of short-lived cytokines in vitro (Baou et al., 2009) , we further characterized the antiangiogenic effect of R9-ZFP36L1 by analyzing the relative abundance of several angiogenic factors in control and R9-ZFP36L1-treated tumors (Figure 9 ). Using mouse angiogenesis antibody arrays, we observed that leptin, interferon-g, acidic fibroblast growth factor, tumor necrosis factor a and interleukin (IL)-6 were the most abundant cytokines detected in LL/2 tumors (Figure 9a ). Overall expression levels of proangiogenic factors were significantly lower in R9-ZFP36L1-treated tumors than in the untreated ones. Densitometry analysis of the arrays revealed that the expression levels of the proangiogenic factors EGF, IL-1a, leptin, acidic fibroblast growth factor, tumor necrosis factor a, IL-6 and TGFa were decreased by 40-90% in R9-ZFP36L1-treated tumors as compared with the untreated ones (Figure 9b) . Consistent with the immunohistochemical analysis ( Figure 8C ), VEGF protein levels were decreased by 70% in R9-ZFP36L1-treated tumors. The most abundant antiangiogenic factors interferon-g and TIMP-1 were decreased by 58 and 28%, respectively.
Discussion
In this study, we hypothesized that ZFP36L1, a regulator of mRNA turnover might represent a novel antiangiogenic agent that may suppress not only VEGF (Ciais et al., 2004; Cherradi et al., 2006) , but also other proangiogenic cytokines that support tumor growth. The development of multityrosine kinase inhibitors has emphasized the superior efficacy of simultaneously targeting several signaling pathways as compared with monospecific inhibitors (Petrelli and Giordano, 2008) . We show that R9-mediated intracellular delivery of ZFP36L1 inhibits tumor growth and is a potent suppressor of tumor vasculature in correlation with a marked decrease in the levels of several tumor angiogenic factors. Our results provide proof of the concept that ZFP36L1-mediated targeting of multiple AREbearing mRNAs is an effective antiangiogenic and antitumoral strategy.
Transfection and transduction studies revealed that PTD-ZFP36L1-mediated decrease of VEGF mRNA levels was associated to a 50% similar decrease in VEGF protein secretion, indicating a direct coupling between VEGF mRNA stability and translation. Although the half-life of ZFP36L1 has been reported to be rather short (3 h) (Benjamin et al., 2006) , PTD-ZFP36L1-induced decrease in VEGF protein levels was detected up to 24 h after their addition to COS7 cells. This observation is in agreement with previous studies showing that some TAT-fusion proteins are still active at least up to 24 h (Cai et al., 2006) . It is worth mentioning that we used low concentrations of purified PTD-ZFP36L1 (100 nM), which is in contrast to previous studies using micromolar concentrations of PTD fusion proteins to transduce different cell types (Richard et al., 2003; Nakase et al., 2004; Duchardt et al., 2007) . We demonstrated that R7-and R9-ZFP36L1 induced a 40% decrease in VEGF protein levels compared with a 20% decrease obtained with TAT-ZFP36L1, thus confirming that arginine-rich ). It is noteworthy that the R7-and R9-mediated decrease in VEGF expression is of a high significance as VEGF expression levels in mammalian cells are tightly regulated. Indeed, a 50% reduction of VEGF expression during embryogenesis, as observed in VEGF þ /À heterozygous mice results in lethality (Carmeliet et al., 1996; Ferrara et al., 1996) .
We assessed the ability of R9-ZFP36L1 to inhibit VEGF expression in vivo by injecting R9-ZFP36L1 into mouse adrenal glands. In the adrenal cortex, the rapid release of corticosteroids into the blood flow is facilitated by a dense vascular network whose maintenance is regulated through strong VEGF expression at the adult stage (Thomas et al., 2004) . A single injection of R9-ZFP36L1 in the adrenal gland induced a massive decrease in VEGF protein levels throughout the adrenal cortex after 24 h, indicating an efficient internalization of R9-ZFP36L1 and probably a bystander effect. Whether this observation results from adrenocortical cell-to-cell transfer of R9-ZFP36L1 remains to be investigated, as we could not determine the coverage of R9-ZFP36L1 in the injected adrenal glands, which do express substantial amounts of endogenous ZFP36L1 (Cherradi et al., 2006) . It should be however noted that protein transduction domains are known to facilitate the passage through the plasma membrane in both directions (Fittipaldi and Giacca, 2005) .
Besides targeting VEGF mRNA, ZFP36L1 could also mediate decay of other ARE-containing mRNAs, such as those encoding inflammatory cytokines, COX-2, the proto-oncogene c-fos, cyclins and the antiapoptotic factor bcl-2, all of which have been reported to be abnormally stabilized in several human tumors (Benjamin and Moroni, 2007) . TTP, the most studied member of ZFP36L1 family has been reported to act as a potent tumor suppressor when overexpressed in a v-Hras-expressing IL-3-dependent mast cells (Stoecklin et al., 2003) . More recently, Essafi-Benkhadir et al (2007) reported that TTP overexpression inhibits RasVal12-dependent tumor vascularization by inducing VEGF mRNA degradation. Whereas transfection experiments yield highly significant information concerning the emerging link between mRNA stability and cancer, inherent limitations of transgenic technologies impede their potential use in human disease therapies. Therefore, additional methods of administrating intracellularly acting proteins are needed to allow in vivo studies. We found that R9-ZFP36L1 exerts a negative effect on tumor progression. Although control tumors displayed a very dense and tortuous vascular network with variability in vessel diameter, a hallmark of excessive VEGF stimulation, R9-ZFP36L1-treated tumors displayed a dramatic loss in tumor vasculature, and a marked reduction in vessel diameter and VEGF levels. These results are in line with those reported by others and showing that inhibition of VEGF signaling partially normalizes tumor vessels (Heath and Bicknell, 2009) .
Profiling protein expression with antibody array analysis of LL/2 tumor extracts revealed that R9-ZFP36L1 targets multiple growth factors (EGF, acidic R9-ZFP36L1 represses multiple tumor angiogenic factors S Planel et al fibroblast growth factor, VEGF and TGFa) and inflammatory cytokines (tumor necrosis factor a, interferon-g, IL-1a and IL-6), all of which are involved in the angiogenic process. Although we cannot exclude the possibility that downregulation of these molecules by R9-ZFP36L1 may be indirect, it is worth mentioning that most of the factors detected with the antibody array are listed in the ARE-mRNA database (ARED; http:// rc.kfshrc.edu.sa/ared), according to their respective ARE clusters. In addition, while VEGF is the only target known for ZFP36L1 in vivo (Bell et al., 2006) , these results were not surprising to us as ZFP36L1, TTP and ZFP36L2 appear interchangeable in ARE-directed mRNA decay assays. Z F P 3 6 L 1 R 9 -Z F P 3 6 L 1 Z F P 3 6 L 1 Figure 6 Injection of PTD-ZFP36L1 in mouse adrenal gland decreases VEGF mRNA and protein levels. (a) ZFP36L1 (negative control) or R9-ZFP36L1 fusion proteins (20 ng) were injected in mouse adrenal gland. Sections of adrenal glands were immunostained for VEGF (brown staining) and counterstained with haematoxylin and eosin (blue staining). Adrenal glands from two control mice (M1, M2) and two R9-ZFP36L1-treated mice (M3, M4) are shown. Scale bar, 100 mm. The brackets delineate the two major zones of the adrenal cortex (ZG, zona glomerulosa; ZF, zona fasciculata). Results from one experiment representative of three independent experiments are shown. (b) RT-PCR analysis of VEGF mRNA in control and R9-ZFP36L1-treated adrenal glands. Hypoxanthineguanine phosphoribosyltransferase was used as internal standard. Results from one experiment representative of two independent experiments are shown.
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and of interferon-g (Ogilvie et al., 2009 ) and IL-12 (Jalonen et al., 2006) .
Our observation that R9-ZFP36L1 is a potent repressor of tumor inflammatory cytokines such as IL-1a, tumor necrosis factor a and IL-6 suggests that R9-ZFP36L1 may also potentially prevent the inflammatory responses that are associated with the development of cancer. Indeed, IL1a has been reported to contribute to tumor angiogenesis and invasiveness in different experimental tumor models (Voronov et al., 2003) . On the other hand, recent data indicate that tumor necrosis factor a not only promotes the production the angiogenic factors IL-8, VEGF and bFGF (Dirkx et al., 2006) , but also induces an endothelial phenotype of monocytes recruited to the tumor site (Li et al., 2009) . Finally, combined targeting of IL-6 and VEGF has been reported to inhibit glioma growth and invasiveness (Saidi et al., 2009 ). In our study, both genes were markedly downregulated by R9-ZFP36L1. Therefore, R9-ZFP36L1 may also potentially control invasive behavior of aggressive tumors. 
Control R9-ZFP36L1
Figure 7 R9-ZFP36L1 inhibits LL/2 tumor growth. Luciferase-expressing LL/2 cells were implanted subcutaneously into nude mice and R9-ZFP36L1 (40 ng), or vehicle were injected into the tumors. Tumor growth was subsequently monitored based on (a) external measurement using caliper (n ¼ 5 for each group, **Po0.01 and ***Po0.001, student's t test), or (b) determination of emitted bioluminescence at day 20. In (b), the right panel represents quantification of the average total flux (photons/sec) in control and R9-ZFP36L1-treated mice (n ¼ 4 for each group, *Po0.05). (c). The difference in tumor volume, as well as in luciferase expression between control and R9-ZFP36L1-treated mice was confirmed by tumor weight. Control weight at the end of the experiment (day 20) was 1116±109 versus 628±32 mg for R9-ZFP36L1-treated tumors (n ¼ 5, **Po0.01).
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Interestingly, although R9-ZFP36L1 treatment also affected some of the antiangiogenic factors expressed in LL/2 tumors, such as interferon-g, IL-12, IP-10 and TIMP-1, the effect of R9-ZFP36L1 on angiogenic factors overcame its effect on antiangiogenic factors as demonstrated by the inhibition of tumor growth and tumor vascularization. It is worth mentioning that, although TIMP-1 is classically considered to inhibit tumor progression, high expression of TIMP-1 has been reported recently to induce MDA-MB-231 tumor growth in severe combined immunodeficiency mice (Bigelow et al., 2008) , and to be associated with adverse prognosis in colorectal and breast human cancers (Kuvaja et al., 2005; Offenberg et al., 2008) .
In conclusion, our study demonstrates the efficiency of a cell-penetrating ZFP36L1 in targeting tumor angiogenesis and tumor growth. We show for the first time that ZFP36L1 is effective in repressing a broad spectrum of target mRNAs bearing structurally distinct AREs in tumor cells. Elevated expression of ZFP36L1 has also been reported to enhance cisplatin sensitivity in head and neck squamous cell carcinoma by reducing the levels of the inhibitor of apoptosis cIAP2 mRNA (Lee et al., 2005) . One could speculate that, in addition to angiogenic genes, R9-ZFP36L1 could also inhibit inducers of resistance to chemotherapy.
Materials and methods
Cloning of PTD-ZFP36L1 fusion proteins
Plasmids containing either the Flag-TAT-, the Flag-R7-or the Flag-R9-ZFP36L1 sequences were constructed as described in details in Supplementary Materials and Methods. (C) Intracellular VEGF immunostaining (brown) in tumor sections from control (e and f) and R9-ZFP36L1-treated mice (g and h). Panels f and h are higher magnifications of areas from e and g. The inset (i) in f shows that no staining was detected when omitting primary anti-VEGF antibody (negative control). Scale bars, 10 mm (a, c, e and g) and 5 mm (b, d, f and h).
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Transfections and luciferase activity assay Transfection of COS7 cells with ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 pTarget plasmids and pLuc-3 0 -UTR (firefly luciferase cloned upstream of VEGF 3 0 -UTR) plasmid, as well as luciferase activity measurement were performed as described in Supplementary Materials and Methods.
SDS-PAGE and western blot analysis
Details are provided in Supplementary Materials and Methods.
Northern hybridization and determination of VEGF mRNA half-life COS7 cells transfected with ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 plasmids (48 h), or incubated with purified ZFP36L1, TAT-ZFP36L1, R7-ZFP36L1 or R9-ZFP36L1 proteins (24 h) were treated with 5,6-dichloro-1-b-dribofuranosyl-benzimidazole (DRB, 10 mg/ml) for increasing periods of time. Total RNA was extracted and subjected to northern blot to determine the VEGF mRNA half-life as described in Supplementary Materials and Methods.
Enzyme-linked immunosorbent assay (ELISA) VEGF content of culture medium from COS7 cells was determined as reported in Supplementary Materials and Methods.
Production of recombinant PTD-ZFP36L1 fusion proteins
Conditions for PTD-ZFP36L1 protein expression and purification are described in Supplementary Materials and Methods. 
Relative intensity Neg Ct Figure 9 R9-ZFP36L1 downregulates the expression of several tumor angiogenic cytokines. (a) Mouse angiogenesis antibody array analysis of control and R9-ZFP36L1-treated tumor extracts. EGF, epidermal growth factor; IL-1a, interleukin-1a; IFNg, interferon g; FGFa, acidic fibroblast growth factor; IL-1b, interleukin-1b; VEGF, vascular growth factor; IL-12, interleukin-12, FGFb, basic fibroblast growth factor; IL-4, interleukin-4; TNFa, tumor necrosis factor a; IP10, interferon inducible protein-10; G-CSF, granulocyte-colony stimulating factor; IL-6, interleukin-6; TGFa, transforming growth factor a; TIMP-1, tissue inhibitor of metalloproteinases-1; Neg Control, negative control; TGFb, transforming growth factor b; TIMP-2, tissue inhibitor of metalloproteinases-2. (b) Quantification of angiogenic proteins in control and R9-ZFP36L1-treated tumors. The arrays presented in (a) were scanned and the relative intensities were analyzed using the ImageJ software. Bars represent the mean ± s.d. of duplicate spots on the array. Experiments were performed twice on two control and R9-ZFP36L1-treated tumors.
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Transduction of PTD-ZFP36L1 proteins in living cells and confocal laser microscopy Uptake and intracellular localization of Alexa 488-labeled PTD-ZFP36L1 proteins were assessed as described in Supplementary Materials and Methods.
Transduction of PTD-ZFP36L1 proteins in vivo Animal experiments were approved by the institutional guidelines and followed the recommendations of the European Community for the Use of Experimental Animals. Female severe combined immunodeficiency mice (6 months old) were purchased from Taconic (Germantown, NY, USA) and maintained in the Animal Resources Center of our department.
In vivo delivery of R9-ZFP36L1 to mice adrenal gland was done by injecting 5 ml of 100 nM solution (20 ng) in phosphate-buffered saline. Control mice were injected with 5 ml of the negative control ZFP36L1 without PTD (20 ng). Mice were sacrificed after 24-48 h (n ¼ 3 in each group). Adrenal glands were collected carefully and either fixed overnight in 4% paraformaldehyde and embedded in paraffin, or processed for total RNA isolation. Tissue sections (5 mm) were immunostained for VEGF.
Reverse transcription-PCR Details on RT-PCR analysis of VEGF or hypoxanthineguanine phosphoribosyltransferase (HPRT) gene expression are provided in Supplementary Materials and Methods.
Tumor growth experiments
In total, 1 Â 10 6 luciferase-transduced LL/2 Lewis Lung Carcinoma cells harvested in 50 ml of medium were mixed with 50 ml of Matrigel (Becton Dickinson, Biosciences, Le Pont de Claix, France), then subcutaneously injected into the hind flank of 10 female nu/nu mice (8 weeks old, 20-25 g, Charles River, France). When tumor size reached B100 mm 3 , mice were divided into two groups. Tumors of the R9-ZFP36L1-treated group were injected every other day with 10 ml of R9-ZFP36L1 diluted in phosphate-buffered saline at a concentration of 100 nM (B40 ng). Tumors of the control group were injected with 10 ml of phosphate-buffered saline containing the same concentration of Tris-glycine as the R9-ZFP36L1 sample. Tumor size was monitored every other day by caliper measurement of tumor length and width . Tumor volume was calculated according to the formula V ¼ 0.5ab 2 , where a and b were the largest and the smallest diameters, respectively. Studies were ended when tumors in the control group reached an average of 1000 mm 3 (day 20-21). To perform tumor imaging, mice were injected with D-luciferin intraperitoneally (150 mg/kg body weight) before being anesthetized with isofluorane. Luciferase expression of the tumors was measured using bioluminescence technology (IVIS Lumina II, Xenogen, Caliper Life Sciences, Villepinte, France) at 15 min after luciferin administration. Measurement of total flux (photons/ sec) of the emitted light reflects the relative number of viable cells in the tumor. Data were analyzed using Xenogen Living Image software (version 3.0). Mice were killed further by cervical dislocation and tumors were excised and weighed before their fixation either in 4% paraformaldehyde or in formalin-free fixative (Accustain, Sigma) to perform immunohistochemistry of VEGF or CD31, respectively.
Immunohistochemistry
In total, 5 mm sections of paraffin-embedded tumors from each group were deparaffinized in xylene and then rehydrated. VEGF and CD31 staining of tumor sections were conducted as described in Supplementary Materials and Methods. Microvascular density of CD31-stained tumors was counted in seven random high-power fields ( Â 200) per tumor section from three R9-ZFP36L1-treated and three control animals and expressed as a number of microvessels per Â 200 field.
Angiogenesis antibody array
Tissue fragments from control or R9-ZFP36L1-treated tumors were lysed in lysis buffer (Promega, Charbonnie`res, France) containing a protease inhibitor cocktail (Sigma, St Louis, MO, USA). In all, 1 mg of total tumor lysate was hybridized to each membrane of an antibody-sandwich mouse angiogenesis array (Panomics, Fremont, CA, USA) according to the manufacturer's guidelines. In two separate experiments, the antibody arrays were hybridized and imaged together. The arrays were scanned and analyzed with the ImageJ software (NIH). Background was subtracted by calculating the pixel intensity for a pixel ring outside the spots and subtracting this baseline value from pixel intensity values within the spots. Interarray normalization was performed by using positive control spots (eight per array) on each array.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism software (version 4, San Diego, CA, USA). Data were analyzed using one-way ANOVA or student's t-test, when appropriate. Results are expressed as means ± s.e.m. A value of Po0.05 was considered as statistically significant.
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